SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

ZLY28

Item No. 38864

Formal Name:	1-(4'-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-[1,1'-biphenyl]-3-yl)cyclopropane-1-carboxylic acid
MF:	$C_{29}H_{23}Cl_2NO_4$
FW:	520.4
Purity:	≥90%
UV/Vis.:	λ_{max}: 265 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥3 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ZLY28 is supplied as a solid. A stock solution may be made by dissolving the ZLY28 in the solvent of choice, which should be purged with an inert gas. ZLY28 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of ZLY28 in these solvents is approximately 30 mg/ml.

Description

ZLY28 is a farnesoid X receptor (FXR) agonist and an inhibitor of fatty acid binding protein 1 (FABP1).[1] It selectively induces reporter gene expression in HepG2 cells expressing human FXR (EC_{50} = 143 nM) over cells expressing 19 other receptors (EC_{50}s = >10,000 nM for all). ZLY28 selectively inhibits FABP1 (IC_{50} = 2.7 µM) over FABP3 (IC_{50} = >30 µM) but also inhibits FABP4 (IC_{50} = 6.3 µM). *In vivo*, ZLY28 (20 mg/kg) induces FXR-related gene expression in the ileum but not the liver in a mouse model of carbon tetrachloride-induced non-alcoholic steatohepatitis (NASH). It also reduces hepatocyte ballooning, as well as hepatic lobular inflammation and steatosis in the same model.

Reference

1. Ren, Q., Chen, Y., Zhou, Z., *et al.* Discovery of the first-in-class intestinal restricted FXR and FABP1 dual modulator ZLY28 for the treatment of nonalcoholic fatty liver disease. *J. Med. Chem.* **66(9),** 6082-6104 (2023).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM